
|
Loading...
Loading...
|
US Pharm. 2010;35(11):8.
Ann Arbor, MI—A drug that grows bone in osteoporosis patients also can heal bone wounds in gum disease patients, according to a University of Michigan study. Patients with severe gum disease received either injections of teriparatide--an anabolic osteoporosis drug--into the abdomen or stomach or placebo for 6 weeks. After 1 year, bone-level measurements in the teriparatide group improved by 29% (a 10-fold increase), versus 3% in the placebo group. Until now, it has been very difficult to reverse bone loss from periodontal disease. The next step is to determine whether the teriparatide treatment could be delivered locally to target site-specific bone healing.
To comment on this article, contact rdavidson@uspharmacist.com.
|
Loading...
Loading...
|
|
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date,
authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings,
including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations,
long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students,
other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn
Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE)
as a provider of continuing pharmacy education.
Copyright © 2000 - 2013 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.
|